Pharmacological studies on novel neurotensin mimetics: Discovery of a pharmacologically unique agent exhibiting concentration-dependent dual effects as antagonist and agonist

Bernadette Cusack, Elliott Richelson, Yuan-Ping Pang, Javid Zaidi, Alan P. Kozikowski

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We report the development of two novel neurotensin mimetics (mimics 1 and 2). These compounds were rationally designed and synthesized according to the multiple template approach. We present results of experiments designed to define their pharmacological profiles. In radioligand binding assays with murine neuroblastoma clone N1E-115, we determined the equilibrium dissociation constants for these compounds at the neurotensin receptor. The Kd values for mimic 1 and mimic 2 were 3.3 μM and 1.9 μM, respectively. Functionally, both mimetics antagonized the neurotensin-stimulated production of cGMP, with Kd values in the low micromolar range. Interestingly, mimic 2 displayed a dualistic pharmacological profile, which was concentration dependent. At doses in the 10-100 μM range, mimic 2 became a full agonist, stimulating cGMP production in N1E-115 cells with an EC50 value of 19 μM. Furthermore, mimic 1 did not antagonize the cGMP response elicited by mimic 2. When the neurotensin receptor was desensitized with a neurotensin receptor agonist, mimic 2 failed to stimulate significant cGMP production. We propose that mimic 2 binds to a higher affinity site when acting as an antagonist and binds to a lower affinity and different site when acting as an agonist. Thus, mimic 2 would appear to represent a unique pharmacological tool to characterize the neurotensin receptor and its diverse binding sites in N1E-115 cells.

Original languageEnglish (US)
Pages (from-to)1036-1040
Number of pages5
JournalMolecular Pharmacology
Volume44
Issue number5
StatePublished - Nov 1993

Fingerprint

Neurotensin
Neurotensin Receptors
Pharmacology
Radioligand Assay
neurotensin mimic 2
Neuroblastoma
Clone Cells
Binding Sites

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacological studies on novel neurotensin mimetics : Discovery of a pharmacologically unique agent exhibiting concentration-dependent dual effects as antagonist and agonist. / Cusack, Bernadette; Richelson, Elliott; Pang, Yuan-Ping; Zaidi, Javid; Kozikowski, Alan P.

In: Molecular Pharmacology, Vol. 44, No. 5, 11.1993, p. 1036-1040.

Research output: Contribution to journalArticle

@article{225bf40a289b444cac87b707c50cebb5,
title = "Pharmacological studies on novel neurotensin mimetics: Discovery of a pharmacologically unique agent exhibiting concentration-dependent dual effects as antagonist and agonist",
abstract = "We report the development of two novel neurotensin mimetics (mimics 1 and 2). These compounds were rationally designed and synthesized according to the multiple template approach. We present results of experiments designed to define their pharmacological profiles. In radioligand binding assays with murine neuroblastoma clone N1E-115, we determined the equilibrium dissociation constants for these compounds at the neurotensin receptor. The Kd values for mimic 1 and mimic 2 were 3.3 μM and 1.9 μM, respectively. Functionally, both mimetics antagonized the neurotensin-stimulated production of cGMP, with Kd values in the low micromolar range. Interestingly, mimic 2 displayed a dualistic pharmacological profile, which was concentration dependent. At doses in the 10-100 μM range, mimic 2 became a full agonist, stimulating cGMP production in N1E-115 cells with an EC50 value of 19 μM. Furthermore, mimic 1 did not antagonize the cGMP response elicited by mimic 2. When the neurotensin receptor was desensitized with a neurotensin receptor agonist, mimic 2 failed to stimulate significant cGMP production. We propose that mimic 2 binds to a higher affinity site when acting as an antagonist and binds to a lower affinity and different site when acting as an agonist. Thus, mimic 2 would appear to represent a unique pharmacological tool to characterize the neurotensin receptor and its diverse binding sites in N1E-115 cells.",
author = "Bernadette Cusack and Elliott Richelson and Yuan-Ping Pang and Javid Zaidi and Kozikowski, {Alan P.}",
year = "1993",
month = "11",
language = "English (US)",
volume = "44",
pages = "1036--1040",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - Pharmacological studies on novel neurotensin mimetics

T2 - Discovery of a pharmacologically unique agent exhibiting concentration-dependent dual effects as antagonist and agonist

AU - Cusack, Bernadette

AU - Richelson, Elliott

AU - Pang, Yuan-Ping

AU - Zaidi, Javid

AU - Kozikowski, Alan P.

PY - 1993/11

Y1 - 1993/11

N2 - We report the development of two novel neurotensin mimetics (mimics 1 and 2). These compounds were rationally designed and synthesized according to the multiple template approach. We present results of experiments designed to define their pharmacological profiles. In radioligand binding assays with murine neuroblastoma clone N1E-115, we determined the equilibrium dissociation constants for these compounds at the neurotensin receptor. The Kd values for mimic 1 and mimic 2 were 3.3 μM and 1.9 μM, respectively. Functionally, both mimetics antagonized the neurotensin-stimulated production of cGMP, with Kd values in the low micromolar range. Interestingly, mimic 2 displayed a dualistic pharmacological profile, which was concentration dependent. At doses in the 10-100 μM range, mimic 2 became a full agonist, stimulating cGMP production in N1E-115 cells with an EC50 value of 19 μM. Furthermore, mimic 1 did not antagonize the cGMP response elicited by mimic 2. When the neurotensin receptor was desensitized with a neurotensin receptor agonist, mimic 2 failed to stimulate significant cGMP production. We propose that mimic 2 binds to a higher affinity site when acting as an antagonist and binds to a lower affinity and different site when acting as an agonist. Thus, mimic 2 would appear to represent a unique pharmacological tool to characterize the neurotensin receptor and its diverse binding sites in N1E-115 cells.

AB - We report the development of two novel neurotensin mimetics (mimics 1 and 2). These compounds were rationally designed and synthesized according to the multiple template approach. We present results of experiments designed to define their pharmacological profiles. In radioligand binding assays with murine neuroblastoma clone N1E-115, we determined the equilibrium dissociation constants for these compounds at the neurotensin receptor. The Kd values for mimic 1 and mimic 2 were 3.3 μM and 1.9 μM, respectively. Functionally, both mimetics antagonized the neurotensin-stimulated production of cGMP, with Kd values in the low micromolar range. Interestingly, mimic 2 displayed a dualistic pharmacological profile, which was concentration dependent. At doses in the 10-100 μM range, mimic 2 became a full agonist, stimulating cGMP production in N1E-115 cells with an EC50 value of 19 μM. Furthermore, mimic 1 did not antagonize the cGMP response elicited by mimic 2. When the neurotensin receptor was desensitized with a neurotensin receptor agonist, mimic 2 failed to stimulate significant cGMP production. We propose that mimic 2 binds to a higher affinity site when acting as an antagonist and binds to a lower affinity and different site when acting as an agonist. Thus, mimic 2 would appear to represent a unique pharmacological tool to characterize the neurotensin receptor and its diverse binding sites in N1E-115 cells.

UR - http://www.scopus.com/inward/record.url?scp=0027424283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027424283&partnerID=8YFLogxK

M3 - Article

C2 - 8246906

AN - SCOPUS:0027424283

VL - 44

SP - 1036

EP - 1040

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -